Cargando…

Dissection of neuroinflammation in schizophrenia

AIMS: Schizophrenia is notoriously becoming one of the world's most debilitating mental disorders, affecting 1 in 100 people. There is increasing evidence that neuroinflammation plays a part in the pathogenesis of schizophrenia and other psychotic disorders; microglial activity acting as a mark...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muratib, Fizah, Mizuno, Yuya, Figueiredo, Ines Carreira, Howes, Oliver, Marques, Tiago Reis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771539/ http://dx.doi.org/10.1192/bjo.2021.730

Ejemplares similares

Neuroinflammation in schizophrenia: meta-analysis of in vivo microglial imaging studies
por: Marques, Tiago Reis, et al.
Publicado: (2019)

T45. THE EFFICACY AND HETEROGENEITY OF ANTIPSYCHOTIC RESPONSE IN SCHIZOPHRENIA: A META-ANALYSIS
por: McCutcheon, Rob, et al.
Publicado: (2020)

The Efficacy and Heterogeneity of Antipsychotic Response in Schizophrenia: A Meta-analysis
por: McCutcheon, Robert A., et al.
Publicado: (2021)

White-matter free-water diffusion MRI in schizophrenia: a systematic review and meta-analysis
por: Carreira Figueiredo, Inês, et al.
Publicado: (2022)

Pre-frontal parvalbumin interneurons in schizophrenia: a meta-analysis of post-mortem studies
por: Kaar, Stephen J., et al.
Publicado: (2019)

O5.5. THE NEUROBIOLOGY OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: MULTI-MODAL PET AND FMRI FINDINGS
por: Howes, Oliver, et al.
Publicado: (2020)

Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measures
por: Osimo, Emanuele Felice, et al.
Publicado: (2018)

Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis
por: Mizuno, Yuya, et al.
Publicado: (2019)

Reduced mu opioid receptor availability in schizophrenia revealed with [(11)C]-carfentanil positron emission tomographic Imaging
por: Ashok, Abhishekh H., et al.
Publicado: (2019)

Adenosine A(2A) receptor in schizophrenia: an in vivo brain PET imaging study
por: Marques, Tiago Reis, et al.
Publicado: (2021)

Impaired theta phase coupling underlies frontotemporal dysconnectivity in schizophrenia
por: Adams, Rick A, et al.
Publicado: (2020)

S153. IMPAIRED THETA PHASE-COUPLING BETWEEN HIPPOCAMPUS AND MEDIAL PREFRONTAL CORTEX IN SCHIZOPHRENIA
por: Adams, Rick, et al.
Publicado: (2020)

Specific and non-specific binding of a tracer for the translocator-specific protein in schizophrenia: an [11C]-PBR28 blocking study
por: Marques, Tiago Reis, et al.
Publicado: (2021)

Reward processing in schizophrenia and its relation to Mu opioid receptor availability and negative symptoms: A [(11)C]-carfentanil PET and fMRI study
por: Shatalina, Ekaterina, et al.
Publicado: (2023)

Tobacco smoking and dopaminergic function in humans: a meta-analysis of molecular imaging studies
por: Ashok, Abhishekh H., et al.
Publicado: (2019)

GABA-A receptor differences in schizophrenia: a positron emission tomography study using [(11)C]Ro154513
por: Marques, Tiago Reis, et al.
Publicado: (2020)

The effect of AUT00206, a Kv3 potassium channel modulator, on dopamine synthesis capacity and the reliability of [(18)F]-FDOPA imaging in schizophrenia
por: Angelescu, Ilinca, et al.
Publicado: (2022)

Association between cannabinoid 1 receptor availability and glutamate levels in healthy controls and drug-free patients with first episode psychosis: a multi-modal PET and 1H-MRS study
por: Borgan, Faith, et al.
Publicado: (2020)

The effects of AUT00206, a novel Kv3.1/3.2 potassium channel modulator, on task-based reward system activation: a test of mechanism in schizophrenia
por: Kaar, Stephen J., et al.
Publicado: (2022)

Animal Models of Relevance to the Schizophrenia Prodrome
por: Petty, Alice, et al.
Publicado: (2021)

F180. CANNABINOID 1 RECEPTOR AVAILABILITY & MEMORY FUNCTION IN FIRST EPISODE PSYCHOSIS: A MULTI-MODAL PET-FMRI STUDY
por: Borgan, Faith, et al.
Publicado: (2018)

Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis
por: Pillinger, Toby, et al.
Publicado: (2020)

Neuroinflammation in schizophrenia: the role of nuclear factor kappa B
por: Murphy, Caitlin E., et al.
Publicado: (2021)

Chemokine Dysregulation and Neuroinflammation in Schizophrenia: A Systematic Review
por: Ermakov, Evgeny A., et al.
Publicado: (2023)

The synaptic hypothesis of schizophrenia version III: a master mechanism
por: Howes, Oliver D., et al.
Publicado: (2023)

Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia
por: McCutcheon, R., et al.
Publicado: (2017)

The neural and molecular basis of working memory function in psychosis: a multimodal PET-fMRI study
por: Borgan, Faith, et al.
Publicado: (2019)

Neuroinflammation and microglial expression in brains of social-isolation rearing model of schizophrenia
por: Ayilara, Gideon Opeyemi, et al.
Publicado: (2023)

Dopamine in major depressive disorder: A systematic review and meta-analysis of in vivo imaging studies
por: Mizuno, Yuya, et al.
Publicado: (2023)

Enhanced Dopamine in Prodromal Schizophrenia (EDiPS): a new animal model of relevance to schizophrenia
por: Petty, Alice, et al.
Publicado: (2019)

Stress and neuroinflammation: a systematic review of the effects of stress on microglia and the implications for mental illness
por: Calcia, Marilia A., et al.
Publicado: (2016)

O11.3. SYNAPTIC MARKER PROTEIN SV2A IS REDUCED IN SCHIZOPHRENIA IN VIVO AND UNAFFECTED BY ANTIPSYCHOTICS IN RATS
por: Chika Onwordi, Ellis, et al.
Publicado: (2020)

Neuroinflammation in Schizophrenia: The Key Role of the WNT/β-Catenin Pathway
por: Vallée, Alexandre
Publicado: (2022)

Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms
por: McCutcheon, Robert A., et al.
Publicado: (2019)

Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats
por: Onwordi, Ellis Chika, et al.
Publicado: (2020)

Brain glucose metabolism in schizophrenia: a systematic review and meta-analysis of (18)FDG-PET studies in schizophrenia
por: Townsend, Leigh, et al.
Publicado: (2023)

Neuroimaging in schizophrenia: an overview of findings and their implications for synaptic changes
por: Howes, Oliver D., et al.
Publicado: (2022)

Alterations in frontal white matter neurochemistry and microstructure in schizophrenia: implications for neuroinflammation
por: Chiappelli, J, et al.
Publicado: (2015)

Abnormal Habituation of the Auditory Event-Related Potential P2 Component in Patients With Schizophrenia
por: Mazer, Prune, et al.
Publicado: (2021)

Comparative Effects of Antipsychotics on Metabolic and Endocrine Function in Children and Young People With Schizophrenia: A Systematic Review and Network Meta-Analysis
por: Rogdaki, Maria, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ksp8c0ecun7dip8ll33mv82hc9